Axovant's Cupboard Is Bare After Lead Dementia Program Fails

'New year, new me' is a mantra to be adopted by Swiss drug developer Axovant as it seeks new products to fill its pipeline. The CNS-focused company is floundering having ended development of its lead compound intepirdine following another clinical trial failure.

Maze — What next for Axovant after failure of dementia drug? • Source: Shutterstock

One week into 2018 and Axovant Sciences Ltd.'s worst fears have been realized; the company has discontinued development of its lead product candidate intepirdine and has little else in its pipeline to retain or regain investor support.

Axovant's stock (traded on NASDAQ) was down 57% on Jan

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Axovant's Cupboard Is Bare After Lead Dementia Program Fails

Read the full article – start your free trial today!

More from Clinical Trials

More from R&D